000307573 001__ 307573
000307573 005__ 20260202090213.0
000307573 0247_ $$2doi$$a10.1038/s43018-025-01097-9
000307573 0247_ $$2pmid$$apmid:41507535
000307573 037__ $$aDKFZ-2026-00068
000307573 041__ $$aEnglish
000307573 082__ $$a610
000307573 1001_ $$00000-0002-1479-8039$$aMoreno-Sanchez, Pilar M$$b0
000307573 245__ $$aImmunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.
000307573 260__ $$aLondon$$bNature Research$$c2026
000307573 3367_ $$2DRIVER$$aarticle
000307573 3367_ $$2DataCite$$aOutput Types/Journal article
000307573 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770019300_1557477$$xReview Article
000307573 3367_ $$2BibTeX$$aARTICLE
000307573 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307573 3367_ $$00$$2EndNote$$aJournal Article
000307573 500__ $$a2026 Jan;7(1):29-42
000307573 520__ $$aPlasticity is a hallmark of aggressive tumors, including glioblastoma (GBM), enabling tumor cells and the tumor microenvironment (TME) to adapt to diverse niches and evade treatment. Here, we discuss how innate and adaptive immune players cooperate in time and space to create an immunosuppressive TME that supports GBM growth and confers resistance to conventional treatments and immunotherapies. We highlight how therapeutic interventions reshape the TME, underscoring the need for targeted approaches to overcome resistance. We introduce the concepts of local TME priming and TME rewiring as necessary foundations for achieving more effective and durable clinical responses in the future.
000307573 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000307573 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307573 7001_ $$aRezaeipour, Mahsa$$b1
000307573 7001_ $$aInderberg, Else Marit$$b2
000307573 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b3$$udkfz
000307573 7001_ $$00000-0002-4160-2521$$aGolebiewska, Anna$$b4
000307573 773__ $$0PERI:(DE-600)3005299-3$$a10.1038/s43018-025-01097-9$$n1$$p29-42$$tNature cancer$$v7$$x2662-1347$$y2026
000307573 909CO $$ooai:inrepo02.dkfz.de:307573$$pVDB
000307573 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000307573 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000307573 9141_ $$y2026
000307573 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2024-12-05$$wger
000307573 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT CANCER : 2022$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000307573 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bNAT CANCER : 2022$$d2024-12-05
000307573 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000307573 980__ $$ajournal
000307573 980__ $$aVDB
000307573 980__ $$aI:(DE-He78)D170-20160331
000307573 980__ $$aUNRESTRICTED